![Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study | British Journal of Cancer Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-018-0244-1/MediaObjects/41416_2018_244_Fig1_HTML.png)
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study | British Journal of Cancer
![Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer | Cell Death & Disease Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer | Cell Death & Disease](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41419-021-04118-4/MediaObjects/41419_2021_4118_Figa_HTML.png)
Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer | Cell Death & Disease
![Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer - ScienceDirect Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0014299914005780-gr1.jpg)
Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer - ScienceDirect
![Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma | Cancer Cell International | Full Text Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma | Cancer Cell International | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12935-019-0767-4/MediaObjects/12935_2019_767_Fig6_HTML.png)
Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma | Cancer Cell International | Full Text
![Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors | Pharmacogenomics Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors | Pharmacogenomics](https://www.futuremedicine.com/cms/10.2217/pgs.12.81/asset/images/medium/figure1.gif)
Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors | Pharmacogenomics
![Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer | American Journal of Physiology-Gastrointestinal and Liver Physiology Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer | American Journal of Physiology-Gastrointestinal and Liver Physiology](https://journals.physiology.org/cms/10.1152/ajpgi.00130.2019/asset/images/medium/zh3001207713r001.png)
Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer | American Journal of Physiology-Gastrointestinal and Liver Physiology
![Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? | British Journal of Cancer Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.bjc.6603860/MediaObjects/41416_2007_Article_BF6603860_Fig1_HTML.jpg)
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? | British Journal of Cancer
![Frontiers | OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma | Oncology Frontiers | OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma | Oncology](https://www.frontiersin.org/files/Articles/698302/fonc-11-698302-HTML/image_m/fonc-11-698302-g006.jpg)
Frontiers | OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma | Oncology
![Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation | Journal of Pharmacology and Experimental Therapeutics Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/377/3/370/F1.large.jpg)
Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation | Journal of Pharmacology and Experimental Therapeutics
![Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer - ScienceDirect Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0014299914005780-gr3.jpg)
Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer - ScienceDirect
![Figure 1 from Failure of Pancreatic Cancer Chemotherapy: Consequences of Drug Resistance Mechanisms | Semantic Scholar Figure 1 from Failure of Pancreatic Cancer Chemotherapy: Consequences of Drug Resistance Mechanisms | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2cb100011ad6a889e9ac747a5c25ebee39db8d6e/3-Figure1-1.png)
Figure 1 from Failure of Pancreatic Cancer Chemotherapy: Consequences of Drug Resistance Mechanisms | Semantic Scholar
![Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway](https://www.spandidos-publications.com/article_images/or/39/3/OR-39-03-1081-g05.jpg)